Jiangxi Fushine Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 28, 2022 at 08:23 am EDT
Share
Jiangxi Fushine Pharmaceutical Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 402.33 million compared to CNY 395.13 million a year ago. Revenue was CNY 402.33 million compared to CNY 395.13 million a year ago. Net income was CNY 27.95 million compared to CNY 74.31 million a year ago. Basic earnings per share from continuing operations was CNY 0.05 compared to CNY 0.14 a year ago. Diluted earnings per share from continuing operations was CNY 0.05 compared to CNY 0.14 a year ago.
Jiangxi Fushine Pharmaceutical Co., Ltd. is principally engaged in research and development, manufacturing and sales of bulk drugs, pharmaceutical intermediates and related products. The Company's main products include sulbactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, tazobactam series enzyme inhibitor bulk drugs, pharmaceutical intermediates and related products, as well as intermediates of carbapenems bulk drugs. The Company distributes its products within domestic markets and to overseas markets, including European Union (EU) and other countries and regions in Asia.